thalidomide has been researched along with Erythema in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A Burmese boy being treated with dapsone (diaminodiphenylsulfone [DDS]), 100 mg daily, for lepromatous leprosy had a fatal reaction to the drug 3 weeks after therapy was started." | 7.66 | Fatal reaction to dapsone during treatment of leprosy. ( Borkowsky, W; Bullock, WE; Frey, HM; Gershon, AA, 1981) |
| "A man in his late 60s who had received the first cycle of a chemotherapeutic regimen of ixazomib, lenalidomide, and dexamethasone for multiple myeloma presented to the dermatologic clinic with a 10-day history of fever and tender lesions on the neck and trunk." | 4.31 | Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma. ( Katayama, S; Ota, M; Yamaga, M, 2023) |
| "These data suggest that the anti-inflammatory effects of thalidomide can affect UVB injury, and may, in part, explain its action in photosensitivity diseases such as cutaneous lupus erythematosus." | 3.72 | Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways. ( Brenneman, S; Burns, R; Gaines, E; Gaspari, A; Haake, A; Lu, KQ; Vink, A, 2003) |
| "A Burmese boy being treated with dapsone (diaminodiphenylsulfone [DDS]), 100 mg daily, for lepromatous leprosy had a fatal reaction to the drug 3 weeks after therapy was started." | 3.66 | Fatal reaction to dapsone during treatment of leprosy. ( Borkowsky, W; Bullock, WE; Frey, HM; Gershon, AA, 1981) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Off-label use of lenalidomide (Len) in chronic lymphocytic leukemia (CLL) is becoming increasingly frequent." | 1.37 | Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. ( Giorgadze, T; Tageja, N; Zonder, J, 2011) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaga, M | 1 |
| Katayama, S | 1 |
| Ota, M | 1 |
| Jia, E | 1 |
| Wei, J | 1 |
| Geng, H | 1 |
| Qiu, X | 1 |
| Xie, J | 1 |
| Xiao, Y | 1 |
| Zhong, L | 1 |
| Xiao, M | 1 |
| Zhang, Y | 1 |
| Jiang, Y | 1 |
| Zhang, J | 1 |
| Fabbro, SK | 1 |
| Kaffenberger, BH | 1 |
| Tageja, N | 1 |
| Giorgadze, T | 1 |
| Zonder, J | 1 |
| Lu, KQ | 1 |
| Brenneman, S | 1 |
| Burns, R | 1 |
| Vink, A | 1 |
| Gaines, E | 1 |
| Haake, A | 1 |
| Gaspari, A | 1 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Lima, V | 1 |
| Brito, GA | 1 |
| Cunha, FQ | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Ribeiro, RA | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Chiou, CC | 1 |
| Shih, IH | 1 |
| Chang, YC | 1 |
| Lee, JC | 1 |
| Kuo, SC | 1 |
| Hong, HS | 1 |
| Yang, CH | 1 |
| Frey, HM | 1 |
| Gershon, AA | 1 |
| Borkowsky, W | 1 |
| Bullock, WE | 1 |
2 reviews available for thalidomide and Erythema
| Article | Year |
|---|---|
Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review.
Topics: Antibodies; Asian People; Cyclosporine; Dermatomyositis; Erythema; Female; Humans; Methotrexate; Mid | 2019 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
8 other studies available for thalidomide and Erythema
| Article | Year |
|---|---|
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multi | 2023 |
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bortezomib; Dexamethasone; | 2014 |
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.
Topics: Erythema; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Sweet S | 2011 |
Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Disease Models, Animal; Dose-Response R | 2003 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Thalidomide-induced severe facial erythema in a patient with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Erythema; Humans; Immunosuppressive Agents; Liver Neoplasms; Male; | 2007 |
Fatal reaction to dapsone during treatment of leprosy.
Topics: Adolescent; Dapsone; Erythema; Humans; Leprosy; Male; Skin; Thalidomide | 1981 |